Current Research Studies
Phase 3, multicenter, randomized, double-blind, group sequential, placebo-controlled study to assess efficacy and safety of rimegepant for the treatment of migraine (with or without aura) in children and adolescents ≥ 6 to < 18 years of age
Rimegepant 311
What is the goal of the study?
To evaluate the efficacy of rimegepant compared with placebo in the acute treatment of migraine in adolescent population (≥ 12 to < 18 years of age) as measured by pain freedom at two hours post-dose.
Who can participate in the study?
Please contact the study team listed below to learn more.